Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998598 | 1.00 | USP2 (0.65) | USP2HTTP2RY10LPAR5LPAR1 | |
| SCHEMBL20124691 | 1.00 | USP2 (0.65) | USP2HTTP2RY10LPAR5LPAR1 | |
| SCHEMBL15295092 | 1.00 | USP2 (0.65) | USP2HTTP2RY10LPAR5LPAR1 | |
| SCHEMBL14848735 | 0.95 | USP2 (0.59) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL14841801 | 0.95 | USP2 (0.59) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL14841798 | 0.95 | USP2 (0.59) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL4814012 | 0.95 | USP2 (0.59) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL14848905 | 0.95 | USP2 (0.59) | USP2HTTP2RY10LPAR5 | |
| SCHEMBL15295109 | 0.93 | USP2 (0.62) | USP2HTTP2RY10LPAR5LPAR1 | |
| SCHEMBL17237747 | 0.92 | USP2 (0.75) | USP2HTTP2RY10LPAR5LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596670-B1 | OILS ENRICHED WITH DIACYLGLYCEROLS AND PHYTOSTEROL ESTERS FOR USE IN THE REDUCTION OF CHOLESTEROL AND TRIGLYCERIDES | ENZYMOTEC LTD (IL) | 2014-05-07 | — | — | EP | disclosed |
| US-8507466-B2 | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | ENZYMOTEC LTD. (IL) | 2013-08-13 | — | — | US | disclosed |
| US-20100184734-A1 | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | ENZYMOTEC LTD. | 2010-07-22 | — | — | US | disclosed |
| US-7375135-B2 | Fatty acid derivatives; preparation and uses thereof | GENFIT (FR) | 2008-05-20 | — | — | US | disclosed |
| EP-1673338-B1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060252827-A1 | Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof | GENFIT (FR) | 2006-11-09 | — | — | US | disclosed |
| US-20060233863-A1 | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | ENZYMOTEC LTD. (IL) | 2006-10-19 | — | — | US | disclosed |
| EP-1673338-A1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | Genfit (FR) | 2006-06-28 | — | — | EP | disclosed |
| US-20060052351-A1 | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress | ENZYMOTEC LTD. (IL) | 2006-03-09 | — | — | US | disclosed |
| EP-1596670-A2 | OILS ENRICHED WITH DIACYLGLYCEROLS AND PHYTOSTEROL ESTERS FOR USE IN THE REDUCTION OF CHOLESTEROL AND TRIGLYCERIDES | Enzymotec Ltd. (IL) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004084646-A2 | COSMETIC COMPOSITIONS COMPRISING PHYTOSTEROL ESTERS | ENZYMOTEC LTD. (IL) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192908-A1 | Fatty acid compounds, preparation and uses thereof | GENFIT (FR) | 2004-09-30 | — | — | US | disclosed |
| WO-2004069150-A2 | OILS ENRICHED WITH DIACYLGLYCEROLS AND PHYTOSTEROL ESTERS FOR USE IN THE REDUCTION OF CHOLESTEROL AND TRIGLYCERIDES | ENZYMOTEC LTD. (IL) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003014073-A1 | FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF | GENFIT (FR) | 2003-02-20 | — | — | WO | disclosed |
| EP-0685234-B1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU CO LTD (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6020317-A | Glycerol derivative, device and pharmaceutical composition | NIPPON SHINYAKU CO. LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0685457-B1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252827-A1 | Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof | SGMS2, SGMS1, AGK | USP2 2389/4885HTT 1822/4885P2RY10 2865/4885 |
| US-20040192908-A1 | Fatty acid compounds, preparation and uses thereof | FASN, FFAR1, PLIN5 | USP2 4008/4885HTT 1016/4885P2RY10 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.